Radiolabeled Glass Beads in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery
Liver Cancer - Metastatic Cancer
Conditions: official terms
Liver Neoplasms - Neoplasm Metastasis - Neoplasms - Neoplasms, Second Primary
Conditions: Keywords
liver metastases, advanced adult primary liver cancer
Study Type
Study Phase
Phase 2
Study Design
Observational Model: Cohort, Time Perspective: Prospective
Name: Yttrium Y 90 glass microspheres
Type: Radiation
Overall Status
RATIONALE: Internal radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. Using radiolabeled glass beads to kill tumor cells may be effective treatment for liver cancer that cannot be removed by surgery.

PURPOSE: This phase II trial is studying how well radiolabeled glass beads work in treating patients with metastatic liver cancer that cannot be removed by surgery.
Detailed Description

- Provide supervised access to treatment with yttrium Y 90 glass microspheres (TheraSphere®) to eligible patients who are not candidates for surgical resection of metastatic intrahepatic carcinoma.

- Evaluate patient experience and toxicities associated with yttrium Y 90 glass microspheres treatment.

OUTLINE: This is a humanitarian device exemption use study.

Patients receive yttrium Y 90 glass microspheres (TheraSphere®) into the liver tumor through a percutaneously placed catheter into the hepatic artery. Patients may receive additional therapy 4-12 weeks after initial treatment at the discretion of the study physician.

After completion of study therapy, patients are followed at 2 weeks, 30 days, and then once a year for approximately 2 years.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both

- Confirmed diagnosis of metastatic intrahepatic carcinoma

- Histopathology confirmation may be waived in patients with a radiographically identifiable liver mass AND known laboratory or clinical risk factors for cancer or elevated tumor markers such as AFP

- Unresectable disease

- No portal hypertension with portal venous shunt away from the liver

- FDA approval to receive compassionate use of yttrium Y 90 glass microspheres

- No significant extrahepatic disease representing an imminent life-threatening outcome

- No evidence of potential delivery of > 16.5 mCi (30 Gy absorbed dose) of radiation to the lungs on either of the following:

- First administration of yttrium Y 90 glass microspheres (TheraSphere ®)

- Cumulative delivery of radiotherapy to the lungs over multiple treatments


- ECOG performance status 0-2

- Life expectancy ≥ 3 months

- Absolute granulocyte count ≥ 1,500/µL

- Platelet count ≥ 25,000/μL

- Creatinine ≤ 2.0 mg/dL (unless using non-iodinated contrast or on dialysis)

- Serum bilirubin ≤ 3.0 mg/dL (in some cases where there is an elevated bilirubin, and the tumor may be isolated from a vascular standpoint, treatment may proceed)

- No contraindication to angiography or selective visceral catheterization, including any of the following:

- History of severe allergy or intolerance to any contrast media, narcotics, sedatives, or atropine, that cannot be controlled using basic angiographic techniques

- Bleeding diathesis, not correctable by usual forms of therapy

- Severe peripheral vascular disease that would preclude catheterization

- No severe liver dysfunction or pulmonary insufficiency

- No active uncontrolled infection

- No significant underlying medical or psychiatric illness

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No evidence of any detectable technetium-99 macroaggregated albumin (Tc-99 MAA) flow to the stomach or duodenum after application of established angiographic techniques to stop such flow

- No comorbid disease or condition that would preclude safe delivery of yttrium Y 90 glass microspheres and place patient at undue risk


- See Disease Characteristics

- More than 4 weeks since prior radiotherapy

- More than 2 weeks since prior surgery

- At least 2 weeks since prior radiosensitizing chemotherapy

- More than 6 weeks since prior carmustine (BCNU) or mitomycin C

- No other concurrent cancer therapy
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
Chicago, Illinois, United States
Status: Recruiting
Contact: Clinical Trials Office - Robert H. Lurie Comprehensive Cancer - 312-695-1301 -
Start Date
December 2004
Completion Date
April 2017
Northwestern University
Northwestern University
Record processing date processed this data on July 28, 2015 page